No profile data available.
DBV Technologies S.a. (0QAJ.IL) is a healthcare company in the allergy treatment pharmaceuticals industry, based in Montrouge, France, with about 88 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$146.95 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was 192.26 million EUR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies.
DBV Technologies reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
192.26 million EUR as of October 9, 2026.
Listed companies of a similar size in the same industry (allergy treatment pharmaceuticals) include Allergy Therapeutics plc (AGY.L).